

CERTIFICATE OF ANALYSIS

LEVEVITAE 1000mg f.c. tablets

Man. Date :28-08-2020
Expiry Date : 08-2023
Pack Lot :0005663
Manuf. Lot : 0004855
Batch Size : 100.000 Tabs
Active Ingredient Lot : LTI0520168-LTI0319084
Active Ingredient Supplier: NEULAND
Man. Site: PHARMATHEN S.A
Pkg. Site: PHARMATHEN S.A
Deviation Report: ☒ NO
☐ YES (the deviation report is attached)

Controls	Specifications	Results
<i>Appearance</i>	White, oblong, biconvex tablets with no defects Dimensions: 22.9±0.1mm x 11.1mm Thickness: 6.7±0.2mm	Conforms 22.9mmX11.1mmX6.7mm
<i>Identification</i>	1.The relative retention time of Levetiracetam peak in the sample solution in relation to the reference solution is RRT = 1.0 ± 0.1 2.UV spectrum of standard correspond to UV spectrum of sample (HPLC – PDA)	1. RRT=1.0 2. Positive
<i>Average mass</i>	1360.0± 5%mg (1292.0–1428.0)mg	1346.8mg
<i>Uniformity of mass</i>	Not more than 2 tablets deviate in mass more than 5% of the reported average mass obtained No tablets deviate in mass more than 10% of the average mass obtained	Min:1321.5mg Max:1374.5mg Conforms
<i>Uniformity of dosage units (Mass Variation)</i>	Acceptance Value (of 10 tablets) ≤ 15.0	1.1
<i>Loss on drying</i>	NMT 4.0%	1.9%
<i>Hardness</i>	NLT 60N	136N Min:123N Max:152N
<i>Assay</i>	95.0 – 105.0% of the stated amount	99.7%
<i>Related substances And Degradation products</i>	Levetiracetam acid NMT 0.10% Any single impurity NMT 0.10% Total NMT 0.50%	Levetiracetam acid: BDL Any single impurity: BQL(LOQ=0.005%) Total: BQL
<i>Enantiomeric purity</i>	NMT 0.50%	BDL
<i>Disintegration</i>	Max. 30 min in water at 37°C ± 1°C	03'.50''- 04'.26''
<i>Dissolution</i>	Apparatus II paddles, 50rpm, Comply with Ph.Eur current edition (introducing S1,S2) % Dissolved: Q=85% of the stated amount in 20 min	93% Min:91% Max:96%
<i>Identification of Titanium Dioxide</i>	Red-Orange colour is produced	Positive
<i>Residual solvents</i>	Ethanol: NMT 2500µg/tablet	283µg/tablet
<i>Microbial contamination</i>	Total Aerobic Microbial count: NMT 1000 cfu/1g Total Yeast and Mould Count: NMT 100 cfu/1g E. Coli: NMT 0 cfu/1g	TAMC:<10cfu/1g TYMC:<10cfu/1g E coli: Absence
<i>Blister tightness</i>	Air and water tight after 30 sec. in 1% methylene blue solution, 160 mmHg pressure	Tight
<i>Packaging</i>	Cardboard box contains the appropriate number of blisters of opaque white PVC / PE / PVDC/Aluminium with the appropriate number of tablets and an instruction leaflet and is printed with Lot, Exp.	Conforms
Responsible for Quality Control	Panagiotis Ivopoulos Quality Control Senior Manager / OP Pharmathen S.A	Release Date :06-10-2020

Pharmathen S.A.

Headquarters: 44 Kifissias Avenue, 151 25 Marousi, Athens Greece, t +30 210 6604 300, f +30 210 6666 749

Manufacturing site-Registered seat: 6 Dervenakion str., 153 51 Pallini, Athens Greece, t +30 210 6604 300, f

+30 210 6604 583

www.pharmathen.com

Prepared by: Athina Tzanakou

**CERTIFICATE OF CONFORMANCE
FOR FINISHED PRODUCT**

NAME OF PRODUCT:	LEVEVITAE 1000mg f.c. tablets		
DOSAGE FORM:	TABLETS	STRENGTH:	1000MG/TAB
PACK SIZE AND TYPE:	BTX3BLISTERX10TABS		
QUANTITY:	3.221BT		
IMPORTING COUNTRY:	GALENICUM CHILE		
BATCH NUMBER BULK:	0004855		
BATCH NUMBER FIN:	0005663		
MANUFACTURE DATE:	28-08-2020	EXPIRY DATE:	08-2023
MANUFACTURING SITE:	Pharmathen S.A		
PACKAGING SITE:	Pharmathen S.A		
BATCH NUMBER OF API:	LTI0520168-LTI0319084_NEULAND		
RESULT OF ANALYSIS:	Certificate of analysis of finished product attached.		
COMMENTS/REMARKS:	-N/A-		
DEVIATIONS:	☐ YES ☒ NO		
	Attached number of documents:		

I hereby certify that the above information is authentic and accurate.

The batch processing, packaging and analysis records were reviewed and found to be in compliance with GMP.

This batch of product, including API, has been manufactured, including packaging and quality control at the above mentioned sites in full compliance with the GMP requirements and the local Regulatory Authority and with the specifications of the Marketing Authorization and is released.


Name of

Qualified Person:

Panagiotis Ivopoulos
Quality Control Senior Manager / QP
Pharmathen S.A

Signature of

Qualified Person:



Date of Release : 06-10-2020

Pharmathen S.A.

Headquarters: 44 Kifissias Avenue, 151 25 Marousi, Athens Greece, t +30 210 6604 300, f +30 210 6666 749
Manufacturing site-Registered seat: 6 Dervenakion str., 153 51 Pallini, Athens Greece, t +30 210 6604 300, f +30 210 6604 583

www.pharmathen.com

Prepared by: Athina Tzanakou